1. Introduction {#sec1}
===============

Coronavirus, the 21st-century pandemic highlights the role of viruses in emerging infectious diseases. It caused a vital onset of lethal pneumonia, initiated by the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic in 2003 ([@bib53]). The SARS-CoV-2 afflicted 213 countries around the world with more than 18 million infections and more than 0.7 million deaths worldwide as on August 5, 2020. The current global plight of COVID-19 is pandemic and the virus continues to sweep the world with no known cure. Coronaviruses are spherical positive RNA viruses in the *Coronaviridae* family with the largest genome amidst all RNA viruses ([@bib73]; [@bib76]). The CoV genomes have non-structural proteins (nsps), replicase (RNA dependent RNA polymerase or rdrp) at 5′ end, open reading frames and structural proteins at 3′ end. The replication gene has two polyproteins (pp1ab and pp1a) for replication and transcription which are converted into 16 nsps by main protease (M^pro^) ([@bib31]). These nsps produce subgenomic RNA encoding the structural proteins: spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins ([@bib76]). The N protein complexes with RNA forming the helical capsid in the viral envelope with other structural proteins embedded inside. The spike proteins projecting from the viral surface carries two domains (S1 and S2) and the receptor-binding domain (RBD) in S1 binds with angiotensin-converting enzyme 2 (ACE2) in host cells to mediate the integration of host and viral cells for viral entry ([@bib7]; [@bib14]). This initiates replication and once inside the host cell, rdrp produces viral mRNA or messenger RNA from template RNA which undergoes translation forming non-structural and structural proteins. The process is error-laden as rdrp lack proofreading functions, increasing the mutation rate within the virus ([@bib67]).

The present-day SARS-CoV-2 has 89% nucleotide similarity and 80% identity with SARS-CoV ([@bib77]). When correlated with Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV, current SARS-CoV-2 shows 96% sequence identity with a bat CoV, RaTG13, indicating a common ancestral origin ([@bib25]; [@bib89]). Despite endeavours to develop a cure after MERS and SARS coronaviruses, vaccines or drugs are still lacking. The antivirals used currently reduce transmission and give symptomatic relief. Current approaches toward anti-corona agents include repurposing of drugs, screening of promising molecules using an extant database or developing a novel vaccine using genomic information of CoVs ([@bib76]). The main drug targets for CoV include the M^pro^, rdrp and spike proteins. An *in-silico* approach of screening existing database to find a variety of compounds inhibiting coronavirus against these targets can save time by filtering out candidates worthy of *in vitro* analysis.

One such set of compounds are flavonoids given in [Table 1](#tbl1){ref-type="table"} ubiquitous in vegetables, fruits, herbs and in traditional medicines ([@bib28]; [@bib39]; [@bib78]). Flavonoids exhibit antiviral ([@bib16]), antibacterial ([@bib82]), antimicrobial ([@bib15]), anticancer ([@bib11]), antidiabetic ([@bib1]), anti-inflammatory ([@bib28]) and antifungal ([@bib72]) properties. Recent reports show quercetin based antiviral drug Gene-Eden-VIR/Novirin inhibiting the protease of SARS-CoV-2 ([@bib51]). Chalcones in flavonoids subset inhibit tobacco mosaic virus ([@bib62]), HIV ([@bib74]), herpes ([@bib27]) and dengue virus ([@bib34]) along with antioxidant ([@bib9]), antimicrobial ([@bib10]), antimycobacterial ([@bib12]) and antileishmanial ([@bib19]) properties. The alkylated chalcones extracted from *Angelica keiskei* inhibit SARS-CoV protease ([@bib49]).Table 1Biological activities of natural flavonoids.Table 1NameCompound CIDBioactivityReferenceLuteolin5280445Inhibition of Japanese encephalitis virus[@bib22]Apigenin5280443Inhibition of Foot-and-mouth disease virus (FMDV) and Enterovirus-71 infection([@bib52]; [@bib86])Tangeritin68077Inhibition of respiratory syncytial virus (RSV)[@bib79]Kaempferol5280863Inhibition of influenza virus[@bib20]Quercetin5280343Inhibition of dengue and influenza virus([@bib75]; [@bib84])Myricetin5281672Inhibition of tobacco mosaic virus and anti-HIV activity([@bib57]; [@bib63])Fisetin5281614Inhibition of enterovirus-A71([@bib35]; [@bib40])Hesperitin72281Inhibition of influenza virus[@bib20]Naringenin932Inhibition of dengue virus([@bib23]; [@bib55])Eriodictyol440735Anti-diabetic, anti-inflammatory and anti-osteoclastogenic agent([@bib69]; [@bib85])Liquiritin503737Anti-inflammatory, antiviral and anti-microbial([@bib13]; [@bib83])Genistein5280961Inhibition of African swine flu virus and herpes virus([@bib3]; [@bib5]; [@bib37])Daidzein5281708Inhibition of herpes virus[@bib6]Calophyllolide5281392Anti-HIV activity[@bib43]Cyanidin128861Anti-HIV activity([@bib32]; [@bib33])Delphinidin68245Inhibition of flavivirus, zika virus and dengue virus[@bib65]Malvidin159287Anti-HIV and anti-RSV[@bib46]Pelargonidin440832Anti-HIV and anti-RSV[@bib46]Peonidin441773Anti-HIV and anti-RSV[@bib46]Phloridzin6072Antiviral, anticancer and cardioprotective agents[@bib26]Arbutin440936Anti-inflammatory and antioxidant agent[@bib45]Phloretin4788Inhibition of zika virus[@bib41]Chalconaringenin5280960Immunomodulation, anti-inflammatory, antiviral, anticancer, and antimicrobial properties[@bib38]

In this study, we have taken 23 natural flavonoids and 25 anti-tubercularly active synthetic indole chalcones ([@bib54]) and studied *in silico* for their potential anti-SARS-CoV-2 activity along with their physicochemical and absorption, distribution, metabolism, excretion, toxicity (ADMET) properties.

2. Materials and methods {#sec2}
========================

The [@bib47] and pkCSM ([@bib50]) servers were used to analyse the pharmacokinetic properties of flavonoids. The crystal structures of proteins were acquired from the RCSB Protein Data Bank (PDB) based on resolution and R factors specifically 6M71, 6YB7, and 6LZG. Homology modelling of selected proteins of SARS-CoV-2 was performed using online server SWISS-MODEL ([@bib56]). The quality of the protein structures was appraised by the Ramachandran plot ([@bib44]) using PROCHECK ([@bib36]) webserver. The proteins were made ready using AutoDock Tools v.1.5.6. to remove unwanted co-crystallized molecules, to add charges (Gaussian, Gasteiger), and to incorporate polar hydrogens. Their energy minimized ligand data was developed on PerkinElmer Chem3D v15.0. Blind docking was achieved using AutoDock Vina v.1.1.2 ([@bib64]) and PyRx-Python Prescription v0.8 ([@bib17]) to assist. Binding affinity for poses with RMSD lower than 2 Å was noted in kcal/mol. Post-docking analysis of protein-ligand interactions was conducted on BIOVIA Discovery Studio Visualizer v.19.1.0. (2018). The synthesis and characterization of indole chalcones were published already by us and the synthetic procedure is available in the literature ([@bib54]).

3. Results {#sec3}
==========

3.1. Pharmacokinetic investigation of flavonoids {#sec3.1}
------------------------------------------------

Pharmacokinetic properties are an elemental segment of drug development to identify the biological properties of drug candidates. Lipinski\'s rule of five ([@bib42]) and Veber\'s rules ([@bib66]) were used to check the drug-likeness. Flavonoids given in [Table 1](#tbl1){ref-type="table"} were analysed for their physicochemical properties and the results are epitomized in [Table 2](#tbl2){ref-type="table"} . The ADMET characteristics of the flavonoids were studied to understand their pharmacokinetic profile and the results are given in [Table 3](#tbl3){ref-type="table"} .Table 2Physicochemical properties of flavonoids under study.Table 2NameLipinski\'s Rule of 5Veber\'s RuleLog PMole. Wt.Hydrogen donorHydrogen acceptorNo. of violationsTotal polar surface area (Å^2^)No. of rotatable bondsLuteolin1.97286.24460111.121Apigenin2.46270.2435090.891Tangeritin3.78372.3707076.386Kaempferol2.17286.24460111.121Quercetin1.68302.24570131.351Myricetin1.39318.24681151.581Fisetin1.97286.24460111.121Hesperitin1.99316.26470120.362Naringenin2.46270.2435090.891Eriodictyol1.97286.24460111.121Liquiritin0.41418.40590145.914Genistein2.27270.2435090.891Daidzein2.56254.2424070.671Calophyllolide6.63414.5004148.684Cyanidin−0.75287.25560112.311Delphinidin−1.04303.25671132.541Malvidin−0.42331.30470110.553Pelargonidin−0.26271.2545092.081Peonidin−0.44301.27460101.322Phloridzin0.40436.417101177.137Arbutin−1.36288.25681139.843Phloretin2.66274.2745097.984Chalconaringenin2.69272.2645097.983[^2]Table 3ADMET properties of flavonoids.Table 3NameAbsorptionDistributionMetabolismExcretionToxicitySolubility\
Log S (log mol/L)Caco-2 perm. (log Papp in 10^−6^ cm/s)Intestinal. absorption. (% Abs)VDss (log L/kg)Fraction.\
Unbound (Fu)BBB perm. (log BB)CNS perm. (log PS)Total clearance (log ml/min/kg)Hepato toxicityAmes toxicityLuteolin−3.0190.64978.930.0650.11−1.185−2.42CYP1A2, CYP3A4 inhibitor0.62NoNoApigenin−2.771.03490.8420.0070.198−0.908−2.168CYP1A2, CYP2C19, CYP2C9 inhibitor0.661NoNoTangeritin−4.3791.42999.904−0.3260.088−0.942−2.958CYP3A4 substrate, CYP1A2, CYP2C19, CYP2C9 inhibitor0.862NoNoKaempferol−3.1910.87982.1390.2340.125−1.189−2.36CYP1A2, CYP2C9 inhibitor0.649NoYesQuercetin−3.2620.73769.7990.3610.067−1.453−3.403CYP1A2 inhibitor0.608NoNoMyricetin−3.030.35755.4820.3330.097−1.797−3.727CYP1A2 inhibitor0.598NoNoFisetin−3.1550.77780.1120.20.094−1.175−2.382CYP1A2, CYP2C9, CYP3A4 inhibitor0.573NoNoHesperitin−3.341.14574.2970.4480.087−1.369−3.314CYP1A2, CYP2C9 inhibitor,0.698NoYesNaringenin−2.771.03490.8420.0070.198−0.908−2.168CYP1A2, CYP2C19, CYP2C9 inhibitor0.661NoNoEriodictyol−3.0190.64978.930.0650.11−1.185−2.42CYP1A2, CYP3A4 inhibitor0.62NoNoLiquiritin−3.681−0.16445.76−0.4310.198−1.419−4.001No0.482NoYesGenistein−2.9450.94291.714−0.0290.154−0.9−2.187CYP1A2, CYP2C19, CYP2C9 inhibitor0.297NoNoDaidzein−3.5310.94993.327−0.1360.221−0.177−1.971CYP1A2, CYP2C19, CYP2C9, CYP2D6 inhibitor0.203NoYesCalophyllolide−6.5750.98997.6230.530.115−0.398−1.44CYP3A4 substrate, CYP1A2, CYP2C19, CYP2C9 inhibitor0.868NoNoCyanidin−3.1920.79978.0130.3040.05−1.395−2.354CYP1A2 inhibitor0.787NoNoDelphinidin−3.0030.70765.8670.2270.073−1.747−3.545CYP1A2 inhibitor0.802NoNoMalvidin−3.6541.04274.8280.3430.048−1.429−3.244CYP1A2, CYP2C9 inhibitor0.927NoNoPelargonidin−3.1480.95788.1810.2840.111−1.124−2.096CYP1A2, CYP2C19, CYP2C9, CYP3A4 inhibitor0.803NoNoPeonidin−3.3980.99682.4890.3420.066−1.307−2.264CYP1A2, CYP2C19, CYP3A4 inhibitor0.857NoNoPhloridzin−3.5070.05141.0070.1670.156−1.751−4.315No0.801NoYesArbutin−2.1890.2741.21−0.1840.425−1.416−4.745No0.722NoNoPhloretin−2.8850.34970.9−0.3610.208−1.261−2.734CYP1A2, CYP2C9, CYP3A4 inhibitor0.263NoNoChalconaringenin−2.8740.40771.479−0.4080.202−1.242−2.618CYP1A2, CYP2C9, CYP3A4 inhibitor0.163NoNo[^3]

3.2. Homology of SARS-CoV-2 proteins {#sec3.2}
------------------------------------

The SARS-CoV-2 proteins, namely RNA dependent RNA polymerase (PDB: [6M71](pdb:6M71){#intref0010}), M^pro^ (PDB: [6YB7](pdb:6YB7){#intref0015}) and Spike protein (PDB: [6LZG](pdb:6LZG){#intref0020}) showed 96.348%, 96.078% and 72.778% sequence identity with rdrp NSP12 (PDB: [6NUR](pdb:6NUR){#intref0025}), main protease (PDB: [2Z9J](pdb:2Z9J){#intref0030}) and spike protein (PDB: [2AJF](pdb:2AJF){#intref0035}) respectively with SARS-CoV. The data indicated that 98.9% (M^pro^, PDB: [6YB7](pdb:6YB7){#intref0040}), 99.4% (spike protein, PDB: [6LZG](pdb:6LZG){#intref0045}) and 99.9% (rdrp, PDB: [6M71](pdb:6M71){#intref0050}) residues are in Ramachandran favoured regions. The Ramachandran plots for each protein are given in supplementary data.

3.3. Protein-ligand docking studies {#sec3.3}
-----------------------------------

Analysis of protein-ligand docking revealed the following: Cyanidin binds at ASP761 catalytic residue on rdrp. Compounds C25, Daidzein, Eriodictyol, Fisetin, Genistein, Kaempferol, Myricetin, Quercetin, Arbutin, Chalconaringenin, Phloretin and Liquiritin interact on the spike proteins' key RBD. Out of 48 compounds, 45 compounds from the library interact with M^pro^ at important residues. The comprehensive list of drugs, their binding affinity and amino acid interactions can be found in the supplementary material in [Fig. S1](#appsec1){ref-type="sec"} and [Table S2](#appsec1){ref-type="sec"} respectively. The important results are discussed in detail in the subsequent sections.

4. Discussion {#sec4}
=============

4.1. Pharmacokinetic investigation of flavonoids {#sec4.1}
------------------------------------------------

Out of 23 natural flavonoids listed in [Fig. 1](#fig1){ref-type="fig"} , nineteen flavonoids are showing no violation of the Lipinski\'s and Veber\'s rules and hence display druglike molecular (DLM) nature. The Log P values of 22 flavonoids are within the range of −1.36 to 3.78, while Calophyllolide shows one violation with a higher Log P value of 6.63. Molecular weight and number of H-acceptors of all flavonoids are within the accepted values of less than 500 and 10 respectively. Myricetin, Delphinidin, Phloridzin and Arbutin show violation in the number of H-bond donors. However, all the flavonoids are following the criteria of Veber\'s rules with total polar surface area (TPSA) values and the count of rotatable bonds within range for oral availability. The indole chalcones given in [Fig. 2](#fig2){ref-type="fig"} are also obeying the aforementioned rules and show excellent DLM properties ([@bib54]).Fig. 1Natural flavonoids used in the current study.Fig. 1Fig. 2Synthetic indole chalcones used in the current study.Fig. 2

The parameters for evaluating the drug absorption was solubility and Caco-2 permeability as listed in [Table 3](#tbl3){ref-type="table"}. The solubility ranges from −6 to −2 indicating the moderate to the high solubility of flavonoids. The high water solubility can be due to 2--6 hydroxy groups present in each compound capable of forming bonds with water molecules. The human colonic adenocarcinoma cell line Caco-2 permeability of 10 compounds are high while myricetin, liquiritin, phloridzin, arbutin, phloretin, and chalconaringenin show poor permeation. The gastrointestinal absorption of the flavonoids is high except for phloridzin, arbutin and liquiritin which only show 40% absorption rate. The low absorption rate of compounds is a direct effect of its molecular size. However, an exception is Calophyllolide showing intestinal absorption of 97% despite its high molecular weight. The distribution of drug candidates considers the volume of distribution (VDss), blood-brain barrier (BBB) permeability, fraction unbound and central nervous system (CNS) permeability. The Log VDss values of less than 0.45 indicate the higher distribution of these drugs in plasma than in the tissues, except for Calophyllolide showing Log VDss vslue of \<0.53. The fraction bound indicates the efficacy with which the compounds can diffuse. The compounds are not BBB permeant as none of the flavonoids has Log BBB \>0.3. In the case of CNS penetration, 15 flavonoids have Log P values from −3 to −2 range, indicating moderate to high permeability. The ability to penetrate CNS is significant as there are reports of coronavirus targeting the CNS, owing to the presence of angiotensin-converting enzyme 2 receptors in neurons and glial cells ([@bib8]). The metabolism and total clearance of the flavonoids were analysed. The flavonoids showed no hepatotoxicity, while 5 compounds showed Ames toxicity and hence may be mutagenic. In a collective sense, the ADMET profile of the flavonoids is satisfactory and hence suitable for *in silico* studies with SARS-CoV-2 proteins.

4.2. Homology of SARS-CoV-2 proteins and protein-ligand docking studies {#sec4.2}
-----------------------------------------------------------------------

Homology modelling revealed that the M^pro^, rdrp and Spike proteins of SARS-CoV-2 are remarkably similar to SARS-CoV in sequence, and their quality based on the Ramachandran plots was adequate for docking study. The anti-coronavirus drug design strategy can be classified based on different pathways of action. These can be the inhibition of proteins like M^pro^ or enzymes which are required for viral RNA replication and synthesis (rdrp) or, the inhibition of structural proteins like spike protein for adhering to host cells by inhibiting the spike -- angiotensin-converting enzyme 2 domain. Interactions between the docked ligands and proteins predict possible modes of action or lack thereof. The compounds with lower binding energy can have a higher affinity towards target proteins. The following sections cover significant docking results and analysis.

### 4.2.1. RNA dependent RNA polymerase (rdrp) {#sec4.2.1}

The replication mechanism of SARS-CoV-2 is chiefly led by rdrp, a complex of nsp12, nsp8 and nsp7 ([@bib29]; [@bib61]). The structure resembles a partially curled right hand grip and can be assorted into three regions namely the palm, the thumb and the fingers ([@bib24]). This rdrp protein (PDB: [6M71](pdb:6M71){#intref0055}) is largely carried over from SARS-CoV and provides certain targets of opportunity ([@bib21]; [@bib24]; [@bib81]) for the selected flavonoids. The key catalytic residue sequence of Ser759, Asp760, and Asp761 on the palm region is the binding site of RNA; assisted in part by Asp618 which is the divalent cation binding residue, these are essential to the replication ([@bib21]; [@bib24]; [@bib81]). Residues, Lys545 and Arg555 stabilize the incoming orientation of RNA while Lys500 and Ser501 mobilize to accommodate its approach ([@bib81]). In addition to these residues, 29--50 on β-hairpin of nsp12 are held responsible for rdrp structural stabilization by interacting with other domains of nsp12 ([@bib81]).

Post docking analysis shows that library members C4, C8, C12, C16, C17, C20, C22, C23, Calophyllolide, Genistein, Quercetin, Tangeritin, Arbutin and Liquiritin interact with β-hairpin residues (29--50). Unfortunately, literature to predict the outcome of these particular β-hairpin interactions in terms of rdrp function or stability is insufficient at present. However, it was encouraging to note that Cyanidin shows H-bonding with Asp761 (as shown in [Fig. 3](#fig3){ref-type="fig"} ) at the RNA binding site with a binding affinity of −7.7 kcal/mol, suggesting that it may hinder the replication mechanism ([@bib81]).Fig. 3Binding mode of Cyanidin to rdrp.Fig. 3

### 4.2.2. Main protease (M^pro^) {#sec4.2.2}

Viral RNA is translated into various polyproteins by the action of the main protease (M^pro^) in SARS-CoV-2 (PDB: [6YB7](pdb:6YB7){#intref0060}) ([@bib2]; [@bib88]). The human equivalent for this particular protease is absent, thus, this is a safe target for anti-SARS-CoV-2 agents. The M^pro^, in active form is a dimer of identical protomers ([@bib48]; [@bib80]; [@bib88]). Each protomer has 3 domains with the region between I and II being the main site of catalysis between residues, Cys145 and His41, while, the cleft between domains II and III is reserved for protomer dimerization ([@bib58]; [@bib88]). The main catalytic site is shaped by the dimerization process which involves the residues between domains II and III ([@bib30]; [@bib71]; [@bib80]). Residues Met6, ARG4, Glu290, and Arg298 are responsible for this monomer-dimer behavior ([@bib71]; [@bib88]). Removal/mutation of these amino acids has shown the loss of M^pro^ activation and reversion to protomer form ([@bib59]; [@bib80]). Catalytic efficiency is regulated by residues 284--286 ([@bib88]), special emphasis on Ala285 ([@bib58]) which is credited with making M^pro^ in SARS-CoV-2 several times more effective than its predecessor, SARS-CoV ([@bib71]). Mutation at Glu288 and Asp289 was also held responsible for disruption of M^pro^ and certain other amino acids such as Lys5 interact with one or more of the aforementioned in a support capacity ([@bib59]). Post docking analysis was astounding as with the exceptions of Arbutin and Calophyllolide almost all the candidates show some form of desirable interaction. Forty compounds at protease regulatory sites and 30 at critical junctures are responsible for activation/shaping of the catalytic site, with 22 compounds common to both categories as shown in [Fig. 4](#fig4){ref-type="fig"} .Fig. 4Sites of compound interaction on M^pro^.Fig. 4

The key sites included are Glu288, Asp289, Glu290, and Lys5 whereas Ala285 and Leu286 are the regulatory sites of interaction. Except for C16 from indole chalcones and 7 flavonoids (Calophyllolide, Daidzein, Luteolin, Peonidin, Tangeritin, Arbutin and Phloridzin), all compounds interact with Leu286. The chalcones, C3 and C12 also interacted with Ala285. Overall, the flavonoids are more favourable with a maximum of three key residue interactions, whereas the indole chalcones are limited to a maximum of two. The best candidates were C23 indole-chalcone with a binding affinity of −10.4 kcal/mol interacting at Glu288, Asp289 and, the flavonoid Quercetin with an additional Glu290 interaction at −9.2 kcal/mol as given in [Fig. 5](#fig5){ref-type="fig"} .Fig. 5Binding mode of Mpro with (a) C23 in 3D (b) C23 in 2D with amino acid interactions (c) Quercetin in 3D (d) Quercetin in 2D with amino acid interactions.Fig. 5

### 4.2.3. Spike (S) protein {#sec4.2.3}

An appealing SARS-CoV-2 target is a spike (S) protein, which attacks the human angiotensin converting enzyme 2 receptors ([@bib60]; [@bib68], [@bib70]; [@bib87]). Recent studies show us the spike protein is split into subunits S1 and S2 by the host proteases; S1 is made up of two domains one C-terminal (CTD) and an N-terminal (NTD) ([@bib70]). The CTD is used by SARS-CoV-2 to bind to, and, it is further divided into external and core subdomains ([@bib70]). This CTD external subdomain is made up of two β-strands attached to a flexible loop and, is primarily responsible for receptor recognition and binding ([@bib70]). Some of the residues that the external subdomain of SARS-CoV-2 S1 CTD uses to bind to the receptor include, Tyr453, Gly496, Gln498, Asn501, Gly502, Tyr503, and Tyr505 ([@bib70]).

These residues are pertinent as seen from the post-docking analysis of compounds. The compounds, C25, Daidzein, Eriodictyol, Fisetin, Genistein, Kaempferol, Myricetin, Quercetin, Arbutin, Chalconaringenin, Phloretin and Liquiritin, evidently all have one or more interactions with these residues. C17 and Luteolin have some minor interaction with residues Asn450 and Arg457 which are adjacent to key sites Tyr449 and Phe456 respectively ([@bib70]). Quercetin proved superior as it was most tightly bound with a −7.8 kcal/mol binding affinity at Gly496, Asn501, Tyr505 and Tyr453 residues as shown in [Fig. 6](#fig6){ref-type="fig"} . These compounds, by occupying specific residues may show some effect in thwarting the spike protein\'s ability to bind and, warrant further study (*in vitro)* of flavonoids as competitive inhibitors of the spike protein.Fig. 6Binding mode of spike protein and Quercetin in (a) 3D (b) 2D with amino acid interactions.Fig. 6

4.3. Structure-activity relationships (SARs) {#sec4.3}
--------------------------------------------

The SARs of the compounds is derived from the interactions at M^pro^ activation/dimerization site as given in [Fig. 4](#fig4){ref-type="fig"}. This was possible for flavonoid compounds and M^pro^, as their large number of interactions provided ample data to interpret. The molecular weight, rotatable bonds and TPSA values of different categories of flavonoids may be similar and hence activity can be related to hydrogen bond donors and acceptors. The number and position of hydroxyl groups especially at 3, 3' and 7 positions ([@bib4]) are significant in explaining the SARs of flavonoids and are marked in [Fig. 7](#fig7){ref-type="fig"} .Fig. 7The general structure of flavonoids.Fig. 7

The study includes flavonoids from seven subcategories. The flavones luteolin, apigenin, tangeritin are showing 3, 2, and 1 each respectively with the binding energy of −8.9 kcal/mol for both luteolin and apigenin. The lower binding energy and higher interactions (3 interactions) of apigenin and luteolin can be assigned to the existence of a hydroxy group at the 7th position of the basic flavonoid structure. The four bulky methoxy groups in tangeritin, however, reduces its interaction to only one protein and also contributes to the higher binding energy of −7.7 kcal/mol. The flavonols category had quercetin, myricetin, kaempferol and fisetin. Here, quercetin and myricetin show interactions with Glu288, Asp289 and Glu290 because of five hydroxyl groups with three --OH groups at 3, 3′ and 7 positions. Kaempferol has four hydroxyl groups with only 2 interactions with Glu288 and Asp289, owing to the absence of --OH at 3' position. However, fisetin with four hydroxyl groups interacts with only one amino acid and has the highest binding energy of −8.7 kcal/mol. Flavones lack an additional --OH group at 3rd position, structurally discriminating them from flavonols and making them less active which is evident from the higher binding energies for same amino acid interactions.

In the case of flavanones, namely, hesperitin, naringenin, eriodictyol and liquiritin, even with the presence of 7 --OH groups, eriodictyol is not interacting with any key residues. The three key interactions of hesperitin can be attributed to the four free hydroxyl groups with three hydroxyl groups in 3, 3' and 7 positions. The number of hydroxyl groups in naringenin is limited to three, with only two in favourable positions and thereby decreasing the number of amino acid interactions to two. However, the presence of beta-D-glucopyranosyl residue at 2nd position and the presence of only one hydroxyl group reduces the interactions of liquiritin to one interaction with Asp289. The result of interaction with isoflavanones was surprising, as daidzein shows interactions with three key amino acids, Glu288, Asp289 and Glu290; while genistein only interacts with Asp289, even though both have only one favourable hydroxyl group at the 7th position. The anthocyanins are structurally similar to flavonols, with the notable absence of C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O in 4th position. Extending the same criteria to anthocyanins, cyanidin and peonidin show three interactions each, and, pelargonidin shows only one amino acid interaction. The lower binding energy of cyanidin (−8.7 kcal/mol) may be due to the presence of five free hydroxyl groups while peonidin (−8.4 kcal/mol) has four free hydroxyl and one methoxy groups.Moving on to chalcones, phloridzin with three hydroxyl groups and one glucoside ring showed three key interactions, followed by chalconaringenin with two key interactions. The indole chalcones were mainly limited to two key interactions. Out of 7 indole chalcones interacting with Glu288 and Asp289, five were heterocyclic compounds. The compound C9, with 3-NH~2~ groups capable of H-bonding, also interacted with the aforementioned amino acids. Three indole chalcones, C3, C6 and C16 only interacted with Asp289. The reason for the lower interaction of indole chalcones when compared to flavonoids can be due to the absence of free hydroxyl groups. In a nutshell, the presence of hydroxy groups is favoring the interactions with key residues, while the position and number of hydrogen bonds are important in analyzing the inhibitory potential. The flavonoids and indole chalcones can be plausible agents against SARS-CoV-2 inhibition and the *in vitro* studies should be implemented to understand their anti- SARS-CoV-2 properties.

5. Conclusion {#sec5}
=============

Natural flavonoids and synthetic indole-chalcones were tested *in silico* for their pharmacokinetic properties and were validated as having druglike nature. This library was considered for tackling the modern-day issue of SARS-CoV-2 and further tested against homology modelled M^pro^, rdrp and S proteins. Analysis of protein-ligand docking revealed the following: Cyanidin may suppress rdrp by binding at Asp761 catalytic residue, halting the viral replication process. Compounds C25, Daidzein, Eriodictyol, Fisetin, Genistein, Kaempferol, Myricetin, Quercetin, Arbutin, Chalconaringenin, Phloretin and Liquiritin interact on the spike proteins' key RBD and may inhibit spread to receptors limiting viral spread. The most encouraging result was that of M^pro^ with a staggering 30 compounds capable of disrupting activation/dimerization of the protease. A whopping 40 compounds could lower the efficiency of M^pro^ by action at regulatory residues. The indole-chalcones and flavonoids displayed the capability to suppress SARS-CoV-2 proteins and justify their further *in vitro in vivo* studies. Quercetin is an established anti-viral agent for dengue and influenza. It displayed strong interactions on SARS-CoV-2 proteins such as M^pro^ at Glu290 and Asp289, as well as on receptor binding domain of the viral spike based on the computational analysis. These results echo the works on Quercetin by other researchers. Hence, Quercetin is an exceptional candidate for further *in vitro/in vivo* studies.
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